
Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They have been bestselling authors, science writers, and science journalists since 1994.More details about their writing at X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu
Potsdam (LabNews Media LLC) – Researchers at the Fraunhofer Institute for Applied Polymer Research IAP have developed a process for encapsulating adhesives in microcapsules, which only then…
Shanghai (LabNews Media LLC) – China's regulatory authority NMPA has approved Satri-cel (CT041, Kaileimei®), the world's first CAR T-cell therapy for the treatment of a solid tumor.…
Bonn (LabNews Media LLC) – The model project for comprehensive diagnostics and therapy finding using genome sequencing has reached an important milestone. Three months after the start of operational…